Blog

Jul 19, 2024, 22:19

Michael Wang: Strong antitumor synergy between venetoclax and A1155463

Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, shared a post on X :

“In Blood Advances, Dolnikova et al of Prague’s Charles University show strong antitumor synergy between the BCL2 inhibitor venetoclax and the BCL-XL inhibitor A1155463 that is preserved even with knockout of BCL2L11. True for MCL, DLBCL, and others.”

Michael Wang

Blockage of BCL-XL overcomes venetoclax resistance across BCL2⁺ lymphoid malignancies irrespective of BIM status published in Blood Advances

Autors: Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener

Source: Michael Wang/X

A1155463 Alexandra Dolnikova bcl-2 inhibitor blood advances cancer Charles University Cristina Daniela Kelemen Dana Sovilj DLBCL Dmitry Kazantsev Eva Hoferkova Eva Pokorna Karel Helman Katerina Machova Polakova Ladislav Andera Liliana Tuskova Magdalena Klanova Marek Mraz Marek Trneny MCL Nikola Curik OncoDaily Oncology Pavel Klener venetoclax

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Special Coverage